From the most recent 10-K, annotated:
As of June 30, 2017 we had 110,344,643 shares of common stock issued, plus:
(1) 1,000,000 shares of preferred stock issued, which is convertible into up to approximately 23,105,348 shares of common stock at the conversion price of $5.41,
[These preferred shares converted to shares of common stock subsequent to the termination of the Licensing and Development Agreement entered into on February 10, 2017 by and between the Company and Seattle Genetics.]
(2) $100 million of principal amount of Convertible Senior Notes convertible into up to approximately 19,583,360 shares of common stock at the conversion rate of $5.11 subject to adjustment as described in the indenture,
[The $100,000,000 Convertible Senior Notes will mature on February 15, 2020, unless earlier purchased or converted, and bear interest at 4.75% semiannually on February 15 and August 15 each year.]
(3) 2,893,240 options to purchase shares of common stock with a weighted-average exercise price of $3.48 per share,
[From the Long-Term Incentive Plan, many expiration dates extending out 7 years.]
(4) 1,831,329 restricted stock units,
[Compensation to the Goldenbergs, subject to arbitration.]
(5) 9,540,417 for potential future grants of options to purchase shares of common stock under the Long-Term Incentive Plan,
(6) warrants to purchase 10,000,000 shares of common stock with an exercise price of $3.75, and
[On October 11, 2016, the Company completed an underwritten public offering of 10 million shares of its common stock and accompanying warrants to purchase 10 million shares of common stock at a purchase price of $3.00 per unit, comprising of one share of common stock and one warrant. The Company received gross and net proceeds of $30.0 million and approximately $28.6 million, respectively after deducting the underwriting discounts and commissions and estimated expenses related to the offering payable. The warrants became exercisable six months following the date of issuance, will expire on the second anniversary of the date of issuance (October 11, 2018), and have an exercise price of $3.75.]
(7) warrants to purchase 8,655,804 shares of common stock with an exercise price of $4.90.
[On February 10, 2017, in connection with the execution of the License Agreement, the Company entered into the Securities Purchase Agreement (“SPA”) with Seattle Genetics. Under the SPA, Seattle Genetics purchased 3,000,000 shares of the Company’s common stock at a price of $4.90 per share, for aggregate proceeds of $14.7 million. Concurrently with the sale of the Common Shares, pursuant to the SPA, the Company also agreed to issue the three-year warrant to purchase an aggregate of 8,655,804 shares of common stock—that is, expiring February 10, 2020. However, on May 4, 2017, the Company and Seattle Genetics entered into a Termination Agreement and agreed to amend the terms of the warrant to amend the expiration date from February 10, 2020 to December 31, 2017.]
Of the 250,000,000 shares of common stock authorized under our Certificate of Incorporation, there are 64,045,859 shares of common stock that remain available for future issuance. |
